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Abstract 
Background: Cognitive Behavioural Therapy (CBT) is the first-choice treatment in the ultra-high risk 
(UHR) for psychosis group. However, CBT is an umbrella term for a plethora of different strategies, 
and little is known about the association between intensity and content of CBT and severity of 
symptomatic outcome.  
Methods: A sample of 268 UHR participants received six months of cognitive behavioural therapy 
with case management (CBCM) in the context of the multi-centre Neurapro trial with monthly 
assessments of attenuated psychotic symptoms (APS). Using multilevel regressions and controlling 
for initial severity of APS, the association between (1) number of CBCM sessions received and 
severity of APS, and (2) specific CBCM components and severity of APS, were investigated.  
Results: In Month 1, a higher number of sessions and more assessment of symptoms predicted an 
increase of APS, while in Month 3, a higher number of sessions and more monitoring predicted a 
decrease in level of APS. More therapeutic focus on APS predicted an increase of APS overall.  
Conclusions: Our findings indicate that the association between intensity/content of CBCM and 
severity of APS in a sample of UHR participants depends on time in treatment. CBCM may positively 
impact severity of APS later in the course of treatment. Therefore, it would seem important to keep 
UHR young people engaged in treatment beyond this initial period. Regarding the specific content of 
CBCM, a therapeutic focus on APS may not necessarily be beneficial in reducing the severity of APS, 
a possibility in need of further investigation.  
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Introduction  
The at-risk-mental state or ultra-high risk (UHR) state describes individuals identified as being at 
enhanced risk of developing a first episode of psychosis, based on the presence of attenuated/short 
lived psychotic symptoms or a significant drop in functioning in the context of a family history of 
psychosis. Since the introduction of the UHR criteria [1], considerable research attention has been 
directed towards the development of effective interventions to positively impact on the trajectory of 
the UHR state. Growing evidence suggests that psychological therapies such as cognitive-behavioural 
therapy (CBT) may provide a safe and effective pre-emptive treatment option in UHR clients [2-7]. 
While recent studies suggest that both psychological and pharmacological interventions reduce rates 
of transition to psychosis, CBT is, given the favourable risk benefit ratio, considered first choice 
treatment in UHR groups [8, 9].  
 
CBT-informed therapy is an umbrella term for a plethora of different strategies that has primarily 
been evaluated as an overall ‘treatment package’ [10] which, in clinical implementation, is carried 
out in a variety of forms [11, 12]. CBT comprises various components such as psychoeducation, case 
formulation, cognitive challenging, or behavioural strategies. Little is known, especially in the field of 
at-risk mental states, about which components of CBT are in fact delivered and if there are specific 
CBT ‘ingredients’ which may be more beneficial than others [10, 13]. Furthermore, the effects of 
frequency or intensity of CBT (i.e., number of sessions delivered) on treatment outcome has only 
been partially investigated [4]. The United Kingdom-based EDIE-2 trial showed that a higher number 
of sessions was associated with less attenuated psychotic symptoms at 12-month follow up [4]. 
Secondary analyses based on this trial evaluated the presence of certain components in cognitive 
therapy from file notes and identified a greater treatment effect if case formulation and homework 
were part of the therapy [13]. Another study in clients with psychosis suggested that CBT was only 
beneficial for those who received the full nine months of CBT. CBT exclusively consisting of 
engagement or assessment was not effective, and the therapy appeared to have a detrimental effect 
on those who did not finish the intervention [10]. 
Although there is evidence for an early (first four weeks) rapid response to CBT for depression [14, 
15], little is known regarding the role of time in treatment in the UHR population. A qualitative study 
in psychosis investigating clients’ experiences of case formulation in CBT suggested that the reaction 
may be subject to change over time: some clients experienced it initially as confrontational, however 
this improved over time in most clients [16]. 
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The current study addresses the need to identify effective components of CBT-informed therapy in 
UHR clients. This may help to develop more targeted and more effective treatment packages for 
future studies and clinical implementation.   
In the present study, a UHR treatment regimen consisting of CBT delivered within a therapeutic case 
management framework (CBCM) was evaluated. In CBCM, the case manager is a central clinician 
who both manages general aspects of the patient’s care and provides psychotherapy.  
The aims of the present study were to (1) characterise the CBCM provided in this study and (2) 
investigate if intensity of CBCM and/or specific CBCM components received predicted the severity of 
subsequent attenuated psychotic symptoms (APS).  
Based on existing literature, it was hypothesised that a greater number of sessions would be 
associated with lower levels of subsequent symptomatology. Exploratory analyses regarding the 
specific CBCM components and time into treatment were also conducted.  
 
 
Method  
Study design and setting 
This study is based on data from the Neurapro trial, a multi-centre, double-blind randomized 
controlled trial investigating the effects of omega-3 polyunsaturated fatty acids (PUFA) versus 
placebo in UHR individuals (ACTRN 12608000475347) [14, 15]. Overall, 304 participants aged 13-40 
years and meeting criteria for UHR status received either omega-3 PUFA together with CBCM, or 
placebo with CBCM. The total study period was 12 months. All participants provided written 
informed consent prior to enrolment to the study. Details on study methodology and RCT results 
have been described in detail previously [14, 15]. The study was presented to participants as a study 
of the effects of a nutritional supplement (omega 3 fatty acids) in addition to a psychosocial 
intervention (CBCM). In other words, the psychological intervention was presented as and viewed by 
participants as integral to the intervention package. No significant differences in any demographic 
characteristics, clinical, functional outcomes or CBCM variables were observed between the 
experimental and control groups at baseline or 12 month follow-up [15]. No significant differences in 
any of these variables were observed at medium term (3.5 years; manuscript in preparation). 
Therefore, CBCM across both groups was used for joint analysis in the current study.  
 
Cognitive-Behavioural Case Management (CBCM) 
CBCM consists of CBT within a case management framework and is globally implemented in 
numerous UHR clinics (for details, please see the PACE Clinic Manual: A Treatment Approach for 
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Young People at Ultra High Risk for Psychosis [16]). All clinicians were extensively trained by senior 
psychologists according to a study-specific CBCM manual prior to study start. The manual consists of 
the following modules: (1) stress management, (2) positive symptoms, (3) negative symptoms, (4) 
basic symptoms, (5) comorbidity. In order to ensure treatment fidelity, regular (fortnightly) 
individual and group supervision was maintained. At the different sites, there was local supervision 
with a senior clinician as well as regular supervision with senior psychologists at the leading site 
(Orygen) via Skype. Sessions were audiotaped with client consent. Session dates and CBCM content 
were recorded using a checklist completed by the clinician after every CBCM session. The checklist 
was divided into 13 CBCM components (see Table 1, first column).  
 
Procedure  
All participants received CBCM adapted to the participant’s level of need and symptom profile within 
the first six months of study enrolment. Symptomatic outcome was assessed at the end of each 
month. Since participants received on average less than one CBCM session in Month 5 and Month 6, 
and 80% of the sessions within the 6-month CBCM period occurred during the first four months, the 
current investigation focused on these first four months (Month 0-Month 4) of CBCM.  
The following variables were created per individual: Number of sessions received (0, 1, 2, 3, 4 or 
more) and number of times each specific component was received.  
 
Outcome Measures 
Severity of attenuated psychotic symptoms (APS) was operationalised as described in Morrison et al. 
[4]: Using the Comprehensive Assessment of At-Risk Mental States (CAARMS [17]), we summed the 
scores of the product of global rating scale score (0-6) and frequency (0-6) of the four subscales 
unusual thought content, non-bizarre ideas, perceptual abnormalities, and disorganised speech.  
 
Statistical methods  
Due to the hierarchical structure of the data (repeated measures (level 1) nested within participants 
(level 2), and participants nested within study sites (level 3)), analysis were conducted using the 
procedure ‘mixed’ for STATA 14.0 for linear mixed models, bootstrapped with 500 replications.  
Additionally, we conducted a sensitivity analysis including ‘completers’ only. A completer was 
defined as a participant who did not drop out, but completed all research interviews.  
 
Number of sessions  
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To investigate the association between number of sessions received and severity of APS while 
accounting for prior symptomatic levels, we applied the same procedure as described in Zilcha-Mano 
et al [19]. Number of sessions during a month was used to predict subsequent severity of APS(T), 
while controlling for prior severity of APS (APS(T-1)). Additionally, we controlled for depressive 
symptoms, gender, age, and number of sessions already received. As the association between 
number of sessions and APS may depend on time in treatment, an interaction term between number 
of sessions and assessment time point (categorical, Month 1-Month 4) was introduced [19]. 
Interaction terms were removed when not significant.  
 
CBCM components  
The same model as described above was applied to investigate the association between specific 
CBCM components and severity of APS.  
Components that may be related to outcome were initially identified in a univariate regression 
model unadjusted for the other components. Components that significantly predicted APS in the 
univariate models and components which constituted more than 15% of the sessions (see Table 1) 
were included in the full, multivariate model, adjusted for the other components. As not all CBCM 
components were received by all participants, each model included only those participants who 
received the component at least once.  
 
Results  
Of the 304 participants randomized in the parent study [15], 268 participants (88%) had at least one 
symptom assessment other than baseline with CBCM checklist data on at least one session available.  
Table 2 displays baseline demographic and clinical information. Participants received on average a 
total of 10.5 sessions (SD 6.02, Range 1-32). The number of sessions per month significantly 
decreased over time (p<.001). The most prevalent CBCM components administered were 
‘monitoring’, ‘stress management’ and ‘assessment of symptoms’ (Table 1). The proportion of the 
components ‘general information/psychoeducation’, ‘monitoring’, ‘assessment of symptoms’, 
‘positive symptoms’, ‘basic symptoms’, and ‘homework’ decreased over time (p<.01). The 
proportion of ‘relapse prevention and termination’ increased with time (p<.001). All other 
components remained stable.  
 
Number of sessions 
In predicting severity of APS, the interaction between number of sessions and assessment time point 
(Month 1 –Month 4) was significant (χ2(3) = 17.93, p<.001). Using Stata’s procedure MARGINS, the 
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slopes per month were subsequently estimated. For Month 1, there was a significant positive 
association between number of sessions and severity of APS: more sessions significantly predicted 
an increase of APS (b = 1.61, SE = .59, p = .007, 95% CI [.44,2.78]). By Month 3, a significant negative 
association between number of sessions and the level of APS was observed: more sessions 
significantly predicted a decrease of APS (b = -1.23, SE = .46, p=.008, 95% CI [-2.14,-.32]). In other 
words, while accounting for the initial severity of APS, each additional CBCM session attendance was 
associated with a 1.6 point increase in severity of APS by the end of the first month, while during 
Month 3, each additional session attended was associated with a 1.2 point reduction of severity of 
APS. Sensitivity analyses using completers only (n=207) yielded similar results: a positive association 
between number of sessions and APS in Month 1 (b = 1.67, SE = .69, p = .016, 95% CI [.32,3.02]), and 
a negative association in Month 3 (b = -1.20, SE = .46, p = .009, 95% CI [-2.10,-.30]).  
 
CBCM Components  
‘Family work’, ‘crisis management’, and ‘relapse prevention/termination’ were a priori excluded 
from analyses because these components constituted less than 15% of the CBCM sessions (see Table 
1). The components ‘psychoeducation’, ‘comorbidity’, ‘negative symptoms’, ‘homework’, and ‘basic 
symptoms’ were not included in the full model as they failed to show an association with APS in the 
univariate models.  
Table 3 provides the results of the full, multivariate models. Included were the components ‘case 
management’, ‘monitoring’, ‘assessment of symptoms’, ‘stress management’ and ‘positive 
symptoms’. ‘Monitoring’ and ‘assessment of symptoms’ showed an interaction with time point, with 
a similar pattern to that seen for number of sessions. There was a positive association between the 
component ‘assessment of symptoms’ and severity of APS during the first month (i.e. more 
assessment, more symptoms). For the component ‘monitoring’, a negative association was observed 
for month 3 (i.e., more monitoring, less symptoms). ‘Stress management’ and ‘case management’ 
did not show a significant association with APS in the full model. The component ‘positive 
symptoms’ demonstrated a positive association with APS (i.e. more focus on positive symptoms, 
more APS) throughout the treatment.  
 
 
Discussion 
Our study investigated the content and intensity of a CBCM regimen in UHR participants provided in 
the context of the Neurapro trial, both descriptively as well as in association with severity of 
attenuated psychotic symptomatology. Our findings indicate that the majority of CBCM occurred 
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within the first four months of the protocol and there was substantial variation in the number of 
sessions received (ranging from 1 to 32 sessions), likely reflecting variation in clients’ clinical 
presentations and varying levels of engagement. The most frequently delivered elements of CBCM 
were ‘monitoring’, ‘stress management’ and ‘assessment of symptoms’.  
In this study, we found that a greater number of sessions predicted a higher level of APS at the end 
of the first four weeks of treatment, an association which was reversed by Month 3 (i.e. more 
sessions was associated with lower level of APS). To our knowledge, our findings are the first to 
indicate that the association between ‘intensity’ of CBCM (i.e., number of sessions received) and 
level of APS may depend on time in treatment. These results appear to be robust as the same 
pattern was observed when a sensitivity approach was applied including completers only.  
These novel findings may be interpreted in several ways. First of all, it is possible that the initial, 
‘unfavourable’ CBCM-APS association is related to a form of response bias. At the beginning of the 
treatment, the amount of psychoeducation regarding UHR is high, potentially leading to a change in 
how and what experiences are revealed compared to the initial assessment. In other words, 
participants may be better informed, better able to describe, and potentially reveal new experiences 
they did not at the initial assessment, leading to a higher rating of APS on the CAARMS for those who 
received more CBCM sessions. Alternatively, the positive association between number of sessions 
and level of APS in the first four weeks may be driven by participants with increasing APS receiving 
more sessions, i.e., an increase in clinical contact in response to worsening symptoms. Similarly, the 
negative association between number of sessions and APS in Month 3 may be driven by participants 
with decreasing APS receiving less sessions. However, the probability of this form of reverse 
causation has been reduced by controlling for the previous level of APS for every participant.  
Conversely, and speculatively, it may be the case that at the very outset of treatment, CBCM is 
associated with an initial intensification of APS. In support of this, Dunn et al.[10] identified a 
potential negative effect of CBT in patients with psychosis who stopped the treatment prematurely. 
Furthermore, a qualitative study on clients’ experience of CBT’s case formulation suggested a change 
over time with some clients experiencing it as confrontational in the beginning, but with an 
improvement of those feelings over time in most clients [18]. Another qualitative study investigating 
the subjective experiences of UHR participants of the EDIE-2 trial indicated that many clients 
disclosed their unusual psychological experiences for the first time in their lives [19]. Clients also 
suggested that talking about these experiences was challenging or difficult [18, 19]. It is conceivable 
that initial confrontation with these unusual experiences at the beginning of CBCM treatment is 
responsible for the initial unfavourable CBCM-APS association. This is speculative and our results 
need to be replicated before firm conclusions can be drawn. It may reflect some traditional views of 
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psychotherapy for psychosis [10, 20]: Talking about the content of psychotic experiences was 
sometimes discouraged from this perspective as it could lead to an aggravation or ‘inadvertent 
collusion’[21]. Most importantly, however, our results suggest that participants may start to benefit 
from more sessions of CBCM when they continue treatment.  
A change in therapeutic alliance may also play a role in the observed association between CBCM 
intensity and APS. Therapeutic alliance is defined as the quality of the relationship between client 
and therapist and is regarded to play a pivotal role in the outcome of psychotherapy [22]. In a 
sample of people with acute first- or second-episode psychosis, Goldsmith et al.[20] showed that 
CBT may have detrimental effects (i.e. worse symptomatic outcome) when the therapeutic alliance 
is poor, and positive effects when the alliance is good. More importantly, improving the therapeutic 
alliance was associated with enhanced outcome [20]. In the current study, the changing association 
between CBCM intensity and APS may be a result of an improving therapeutic alliance over time. 
Finally, it is also possible that initially, CBT is somewhat difficult for this client group to engage with, 
possibly due to it being an overly formalised approach that may be challenging for young people, 
particularly when distressed and being oriented to a new service [2]. This interpretation would 
suggest that a therapeutic approach that emphasises engagement, ‘meeting the person where they 
are at’ and is possibly more supportive and person-centred in nature may be indicated in the very 
early phases of treatment for this group, before moving onto more concerted or focused CBT 
techniques. 
Regarding the CBCM components, only the components ‘monitoring’, ‘assessment of symptoms’, 
and ‘positive symptoms’ were significantly associated with severity of APS in the full model. 
‘Monitoring’ and ‘assessment’ followed the same pattern as number of sessions: In interaction with 
time, ‘assessment of symptoms’ was positively associated with APS (i.e. more assessment, higher 
level of symptoms) during the first month only, while this association changed its direction in month 
3 (without reaching significance). ‘Monitoring’ was negatively associated with APS in month 3 only 
(i.e. more monitoring, less APS), and an investigation of the coefficients shows that also in this case, 
the association changed its direction compared to month 1.  
The finding regarding the component ‘positive symptoms’ followed a different pattern. More focus 
on positive symptoms predicted a higher level of APS across the investigated intervention period (i.e. 
no interaction with time). Again, this finding can be interpreted in a number of ways. First, while we 
control for level of APS during the previous assessment, it is still possible that participants 
demonstrate increasing APS in the few weeks prior to a research assessment. This may be picked up 
by the clinician, who responds with an increased focus on APS during CBCM sessions. Conversely and 
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speculatively, focusing on APS may not be beneficial in decreasing its level, in line with what is 
discussed and reviewed above.  
The fact that most other components did not show significant associations with symptomatic 
outcome may be due to a lack of power, and more research in larger samples is required.  
As this study was a secondary analysis of the Neurapro trial and was not specifically designed to 
evaluate CBCM, it comes with the clear limitations of no control group (i.e., a group who received no 
CBCM or a different form of psychotherapy). Furthermore, components were not randomly 
assigned, but selected on the basis of participant presentation. Although the current analytical 
approach (i.e. controlling for previous symptomatic levels) reduced the possibility of reverse 
causation, we cannot ascertain cause and effect. That is, symptomatic levels may be impacted by 
CBCM, CBCM may be impacted by participant presentation, or both. Furthermore, it is likely that the 
different components may interact in impacting on symptomatic levels and there may be order 
effects of the specific CBCM components. Moreover, we were not able to investigate certain 
components (i.e., crisis management, family intervention) as these elements were delivered 
infrequently. However, our exploratory study can be used to generate hypotheses to be 
experimentally tested in the future. In light of psychotherapeutic interventions being a preferred 
option to medication in young people at risk of psychotic disorder, it is important to identify the 
active ingredients or key components of CBT-informed therapies. Recommendations for future 
studies are dismantling studies or trials randomising participants to components. Furthermore, it is 
important to measure therapeutic alliance over the course of CBT intervention and capture the 
detailed subjective experience of the participants. Understanding the specific structure (e.g., 
duration) and content (components) of CBT that is most effective for symptoms in this patient group 
can critically inform future treatment.  
 
Our findings, while preliminary, indicate that the association between intensity/content of CBCM 
and severity of APS in a sample of UHR participants depends on time in treatment. CBCM may 
positively impact APS only later in the course of treatment, after an initial refractory phase. 
Therefore, it may be important for clinicians to keep UHR young people engaged in treatment 
beyond this initial period and to increase awareness and validation of the potentially confronting 
and destabilising nature of talking about and discussing APS often for the first time. Alternatively, 
therapeutic approaches that emphasise engagement, possibly more supportive and person-centred 
in nature, may be indicated in the very early phases of treatment for this group. Furthermore, a 
therapy focus on positive symptoms may not be beneficial for all clients throughout treatment. In 
line with the suggestions of Richardson and Doster [23], clinicians need to carefully balance 
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treatment along three dimensions of baseline risk (i.e. the risk the person would be at without 
treatment), expected responsiveness to treatment, and possible vulnerabilities (e.g. possible adverse 
effects) imposed by the treatment [24]. Future studies that randomise participants to CBCM or CBT 
components are needed to replicate the current findings and ascertain cause and effect. 
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Table 1. Components of cognitive-behavioural case management 
Components  % of sessions 
Included in analysis  
Monitoring  68.4 
Stress Management 51.3 
Assessment of symptoms 48.2 
Comorbidity 39.4 
Negative symptoms  38.8 
Homework 37.6 
Positive symptoms 30.3 
Case Management 21.7 
General Information/Psychoeducation 21.3 
Basic Symptoms 17.3 
  
Not included in analysis a  
Crisis Management 14.4 
Family Work 14.4 
Relapse Prevention and Termination 10.9 
  
  
a Excluded as these elements constituted less than 15% of the sessions 
 
 
Table 2.Baseline demographic and clinical data (N=268) 
Characteristic Mean (SD, Range) or N (%) 
 Age 18.9 (4.35, 13-37)  
Gender Female 146 (54%) 
Male 122 (46%) 
Ethnicity Caucasian 216 (80%) 
Black or African American 7 (3%) 
Asian 35 (13%) 
Other 10 (4%) 
Education Primary school 105 (39%) 
Secondary school, discontinued 49 (18%) 
Secondary school, completed 71 (27%) 
Trade or technical training 28 (11%) 
Undergraduate university course 14 (5%) 
Missing 1 (0%) 
 APS 37.3 (16.89, 0-96) 
 MADRS 19.3 (8.92, 0-39)  
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Table 3. Results for the mixed model investigating the association between cognitive-behavioural case management 
component and level of attenuated positive symptoms. When interactions with time were not significant, the overall effect 
was estimated.  
Component   Component by 
time (interaction) 
Coefficient (SE) [95% CI] per month 
(simple slopes) 
Coefficient (SE) [95% CI] 
overall (main effect) 
APS     
Case Management 
(N=140) 
χ2(3) = 5.51 - b = -.23 (.61) [-1.44,.97] 
Monitoring 
(N=233) 
χ2(3) = 11.06** Month 1: b = .36 (.66) [-.94,1.66] - 
Month 2: b = -1.04 (.66) [-2.33, .25]  
Month 3: b = -1.55 (.60) [-2.73,-.37]**  
Month 4: b = .03 (.83) [-1.58,1.65]  
Assessment 
(N=215) 
χ2(3) = 8.01* Month 1: b = 1.49 (.59) [.33,2.65]** - 
Month 2: b = .27 (.76) [-1.22,1.75]  
Month 3: b = -.86 (.85) [-2.52,.81]  
Month 4: b = 1.29 (.96) [-.59,3.16]  
Stress Management 
(N=229) 
χ2(3) = 5.38 - b = -.44 (.45) [-1.32, .44] 
Positive symptoms 
(N=174) 
χ2(3) = 2.63 - b = 1.69 (.60) [.51,2.87]** 
***=p<.001; **=p<.01; *=p<.05; T=p<.057 
CBCM, cognitive-behavioural case management; APS, attenuated psychotic symptoms 
 
